$DVA

Waters Kathleen Alyce sold $3.2M of DVA

Waters Kathleen Alyce (Chief Legal & Pub. Affairs Off) sold 15,405 shares of DAVITA INC. (DVA) at an average of $208.40 ($207.84–$209.17, $3.21M total) across 2 trades on 2026-06-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Waters Kathleen Alyce
Published Jun 17, 2026, 10:10 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 17, 2026, 10:11 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$DVA
Neutral
high confidence
Mentioned
$DVA
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DVANeutralLow
01

Why it matters

The disclosed open-market sale is primarily a transparency datapoint; without additional company news, it is unlikely to materially change valuation drivers.

02

Market read

Traders may monitor for follow-on insider activity, but the filing alone does not introduce a new fundamental catalyst.

03

What to watch

The article provides only the sale details; it does not include any offsetting insider buys, changes in guidance, or other fundamental updates that would contextualize the selling.

Relevance 5/10Novelty 5/10Timing: Filed 2026-06-17; sale executed 2026-06-15.

Background

The article is an SEC Form 4 insider transaction disclosure for DaVita, reported by an officer under a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$DVANeutralHigh confidence
Context

DaVita insider (Chief Legal & Public Affairs Officer) sold 15,405 shares in open-market trades under a pre-arranged 10b5-1 plan for ~$3.21M.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a Form 4 detailing a planned 10b5-1 sale with no accompanying company-specific operational/regulatory catalyst in the text.

Market effects

Minimal—this is company-specific insider transaction disclosure with no sector-wide read-across provided.

None indicated.

None indicated.

Counterpoint

Even planned 10b5-1 sales can coincide with private information; traders may still treat the disclosure as a mild negative signal for positioning.

Key entities

  • DAVITA INC.

    Issuer of the Form 4 insider transaction; officer sold 15,405 shares for ~$3.21M under a 10b5-1 plan.

  • Waters Kathleen Alyce

    Chief Legal & Public Affairs Officer who executed the open-market sale(s).

Related articles

$DVAMed

DaVita Shares Rise After TD Cowen Upgrades Stock to Buy

DaVita HealthCare Partners (NYSE:DVA) rose about 2.1% premarket after TD Cowen upgraded it from Hold to Buy and raised its price target to $220 from $201, citing improving competitive position and long-term growth. The upgrade followed DaVita’s Q2 2026 results: adjusted EPS $4.02 vs $3.92 expected, revenue about $3.55B vs estimates, while guidance stayed unchanged.

$DVAMed

Why is DaVita stock up 2% today?

DaVita HealthCare Partners (DVA) rose about 2.1% in pre-open trading after TD Cowen upgraded it from Hold to Buy and raised its price target to $220 from $201, citing improving competitive position and MOTheR trial results. The upgrade followed DaVita’s Q2 2026 beat, with adjusted EPS of $4.02 vs $3.92 and revenue of about $3.55B vs forecasts, despite flat guidance.

$DVAMed

DaVita Inc. Q2 2026 Earnings Call Summary

DaVita reported Q2 2026 updates on dialysis operations, citing improved patient mortality and a Medicare bundle shift that reduced reliance on OTC phosphate binders by over 50%. Revenue per treatment fell sequentially. DaVita reconfirmed 2026 adjusted operating income guidance of $2.2B and expects 2026 treatment growth at the top of 25-50 bps. FDA approval of NIPRO expanded HD dialyzers may improve supply.

$DVAMed

DaVita Q2 Earnings Call Highlights

DaVita (NYSE:DVA) reported Q2 earnings call highlights. Revenue per treatment fell about $2 sequentially, while patient care costs per treatment dropped about $3. Full-year guidance remains 1% to 2% revenue-per-treatment growth and adjusted operating income midpoint of $2.2B, EPS $14.65. CMS proposed adding phosphate binders to 2027 dialysis bundles; DaVita plans expanded HD deployment.